AI assistant
Protara Therapeutics, Inc. — Director's Dealing 2024
Jun 27, 2024
34057_dirs_2024-06-27_44d5851b-8a6a-480f-aac6-743ba8cb4d3d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Protara Therapeutics, Inc. (TARA)
CIK: 0001359931
Period of Report: 2024-06-25
Reporting Person: Opaleye Management Inc. (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-06-25 | Common Stock, par value $0.001 per share | S | 6500 | $2.2581 | Disposed | 2266359 | Indirect |
| 2024-06-25 | Common Stock, par value $0.001 per share | S | 6225 | $2.2581 | Disposed | 102471 | Indirect |
Footnotes
F1: Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
F2: Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.25-$2.26 inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each price.